C—Side by side
Compare
Up to four peptides. Opinion rows are labeled. Copy the URL to share.
| Field | Tesamorelin | Ipamorelin |
|---|---|---|
| Type | FDA Approved | Research Only |
| Regulatory status | FDA-approved (Egrifta formulations) | Not FDA-approved; no verified marketing authorization |
| Compounding status | Approved product (not applicable) | Not cleared (advisory panel rejected) |
| FDA-approved indications | Reduction of excess abdominal fat in HIV-infected adults with lipodystrophy; not indicated for weight-loss management. | None |
| Categories | Growth hormone axis | Growth hormone axis |
| Claimed uses |
|
|
| Mechanism | Growth hormone-releasing hormone analogue that stimulates pituitary growth hormone secretion and increases IGF-1. | Ghrelin-receptor agonist that stimulates growth-hormone release and can affect gastrointestinal motility. Hormone release alone does not establish anti-aging benefit. |
| Evidence level | Human RCTs (approved use) | Small/early human studies |
| Evidence / Hype (opinion) | Evidence Hype | Evidence Hype |
| Momentum (opinion) | Steady | Watch |
| Routes | Injection | — |
| WADA | Prohibited | Prohibited |
| Where it stands (opinion) | A narrowly indicated approved medicine, not a general anti-aging treatment. WADA 2026 S2.2.4 prohibits growth hormone-releasing factors, including tesamorelin. | Historical phase 2 research does not establish wellness efficacy. Its 503A nomination was withdrawn; acetate remains Category 2 under 503B, and WADA 2026 S2.2.4 prohibits it. |
| Last reviewed | 2026-10-30 | 2026-10-30 |
| News (30d) | 0 | 0 |